Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Genprex, Inc. (GNPX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.2900-0.0500 (-2.14%)
At close: 4:00PM EDT
2.3000 +0.01 (+0.44%)
After hours: 05:36PM EDT
Advertisement

Genprex, Inc.

3300 Bee Cave Road
Suite 650-227
Austin, TX 78746
United States
877 774 4679
http://www.genprex.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Mr. John Rodney VarnerCo, Founder, Pres, CEO, Sec. & Chairman750.94kN/A1957
Mr. Ryan M. Confer M.S.Chief Financial Officer522.53kN/A1982
Ms. Catherine M. VaczyExec. VP, Gen. Counsel & Chief Strategy Officer646.02kN/A1961
Mr. Michael T. RedmanExec. VP & COON/AN/A1955
Ms. Kalyn DabbsSr. Mang. of Communications & MarketingN/AN/AN/A
Mr. Thomas C. Gallagher Esq.Sr. VP of Intellectual Property & LicensingN/AN/AN/A
Dr. William E. Gannon Jr.Member of Clinical Advisory Board & VP of Regulatory AffairsN/AN/AN/A
Dr. Jack A. Roth F.A.C.S., FACS, M.D.Chairman of Scientific & Medical Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Corporate Governance

Genprex, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement